TY - JOUR
T1 - Compatibility of fosfomycin with different commercial peritoneal dialysis solutions
AU - Kussmann, M
AU - Baumann, A
AU - Hauer, S
AU - Pichler, P
AU - Zeitlinger, M
AU - Wiesholzer, M
AU - Burgmann, H
AU - Poeppl, W
AU - Reznicek, G
N1 - Publisher Copyright:
© 2017, The Author(s).
PY - 2017/11/1
Y1 - 2017/11/1
N2 - For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal®, Nutrineal®, Physioneal® 1.36% and Physioneal® 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C). Drug concentrations over time were determined by using high-performance liquid chromatography coupled to a mass spectrometer. In addition, drug activity was assessed by a disk diffusion method, diluent stability by visual inspection and drug adsorption by comparison of the measured and calculated concentrations. Blank peritoneal dialysis fluids and deionized water were used as comparator solutions. Fosfomycin was stable in all peritoneal dialysis fluids and at each storage condition investigated over the whole study period. The remaining drug concentrations ranged between 94% and 104% of the respective initial concentrations. No significant drug adsorption was observed for any peritoneal dialysis fluid at any storage condition. No relevant reduction of antimicrobial activity was observed. Fosfomycin is compatible with Extraneal®, Nutrineal® and Physioneal® for up to two weeks at refrigeration or room temperature and may be used for home-based therapy. No dose adjustment is needed due to adsorption or degradation.
AB - For treatment of peritoneal dialysis-related peritonitis, intraperitoneal administration of antibiotics remains the preferable route. For home-based therapy, patients are commonly supplied with peritoneal dialysis fluids already containing antimicrobial agents. The present study set out to investigate the compatibility of fosfomycin with different peritoneal dialysis fluids, namely, Extraneal®, Nutrineal®, Physioneal® 1.36% and Physioneal® 2.27%, under varying storage conditions. The peritoneal dialysis fluid bags including 4 g fosfomycin were stored over 14 days at refrigeration temperature (6°C) and room temperature (25°C) and over 24 h at body temperature (37°C). Drug concentrations over time were determined by using high-performance liquid chromatography coupled to a mass spectrometer. In addition, drug activity was assessed by a disk diffusion method, diluent stability by visual inspection and drug adsorption by comparison of the measured and calculated concentrations. Blank peritoneal dialysis fluids and deionized water were used as comparator solutions. Fosfomycin was stable in all peritoneal dialysis fluids and at each storage condition investigated over the whole study period. The remaining drug concentrations ranged between 94% and 104% of the respective initial concentrations. No significant drug adsorption was observed for any peritoneal dialysis fluid at any storage condition. No relevant reduction of antimicrobial activity was observed. Fosfomycin is compatible with Extraneal®, Nutrineal® and Physioneal® for up to two weeks at refrigeration or room temperature and may be used for home-based therapy. No dose adjustment is needed due to adsorption or degradation.
KW - Anti-Bacterial Agents/therapeutic use
KW - Dialysis Solutions/therapeutic use
KW - Disk Diffusion Antimicrobial Tests
KW - Drug Interactions
KW - Fosfomycin/therapeutic use
KW - Gram-Negative Bacteria/drug effects
KW - Gram-Negative Bacterial Infections/drug therapy
KW - Gram-Positive Bacteria/drug effects
KW - Gram-Positive Bacterial Infections/drug therapy
KW - Humans
KW - Peritoneal Dialysis/adverse effects
KW - Peritonitis/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85021923843&partnerID=8YFLogxK
U2 - 10.1007/s10096-017-3051-3
DO - 10.1007/s10096-017-3051-3
M3 - Journal article
C2 - 28685187
SN - 0934-9723
VL - 36
SP - 2237
EP - 2242
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
IS - 11
ER -